✦ LIBER ✦

A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis

✍ Scribed by William C. Small; Debra DeSimone-Macchi; John R. Parker; Arun Sukerkar; Peter F. Hahn; Daniel L. Rubin; James V. Zelch; Janet E. Kuhlman; Eric K. Outwater; Jeffrey C. Weinreb; Jeffrey J. Brown; Eduard E. de Lange; Paula J. Woodward; Ronald Arildsen; Gregory S. Foster; Val M. Runge; Alex M. Aisen; Lawrence R. Muroff; Ruedi F. Thoeni; Yuri R. Parisky; Lawrence N. Tanenbaum; Saara Totterman; Robert J. Herfkens; John Knudsen; Robert E. Laster; Jr.; Andre Duerinckx; Arthur E. Stillman; Charles E. Spritzer; Sanjay Saini; Neil M. Rofsky; Michael E. Bernardino

Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 296 KB
Volume: 10
Category: Article
ISSN: 1053-1807
DOI: 10.1002/(sici)1522-2586(199907)10:1<15::aid-jmri3>3.0.co;2-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A p(O2)-Responsive MRI Contrast Agent Ba

A p(O2)-Responsive MRI Contrast Agent Based on the Redox Switch of Manganese(II / III) – Porphyrin Complexes

✍ Silvio Aime; Mauro Botta; Eliana Gianolio; Enzo Terreno 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 2 views

A p(O2)-Responsive MRI Contrast Agent Ba

A p(O2)-Responsive MRI Contrast Agent Based on the Redox Switch of Manganese(II / III) – Porphyrin Complexes

✍ Silvio Aime; Mauro Botta; Eliana Gianolio; Enzo Terreno 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

Contrast in magnetic resonance imaging (MRI) is largely determined by differences in the relaxation times of protons in tissues. Therefore, contrast agents (CAs) for this diagnostic methodology have mainly been sought among the coordination compounds of metal ions with several unpaired electrons, [

Safety and Efficacy of Mangafodipir Tris

Safety and Efficacy of Mangafodipir Trisodium (MnDPDP) Injection for Hepatic MRI in Adults: Results of the U.S. Multicenter Phase III Clinical Trials (Safety)

✍ Michael P. Federle; Judith L. Chezmar; Daniel L. Rubin; Jeffrey C. Weinreb; Patr 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Efficacy and safety of mangafodipir tris

Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging

✍ Michael Federle; Judith Chezmar; Daniel L. Rubin; Jeffrey Weinreb; Patrick Freen 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 549 KB

A phase 3 randomized controlled trial of

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro

Efficacy and safety of the PPARγ partial

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta